SCHEMBL4050889

SCHEMBL4050889

Cn1nc(OS(=O)(=O)C(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.56
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.45
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GAA P10253 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.35
PTGES2 Q9H7Z7 1/20 0.33
POLB P06746 1/20 0.32
DRD2 P14416 2/20 0.32
DRD3 P35462 2/20 0.32
HTR1D P28221 1/20 0.32
CHRM1 P11229 1/20 0.31
DRD4 P21917 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4C Q08493 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3057367 0.77 PKM (0.46) PKMNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL16141253 0.76 DRD2 (0.38) PKMDRD2DRD3HTR1DCHRM1
SCHEMBL3382600 0.75 PKM (0.57) PKMNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL17662695 0.75 PKM (0.38) PKMNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL4051076 0.75 PTGS2 (0.41) RAB9ASMN1; SMN2NPSR1ALDH1A1
SCHEMBL5610475 0.75 PKM (0.40) PKMNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL8111889 0.74 PKM (0.55) PKMNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL17473215 0.74 PKM (0.37) PKMNPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL20798394 0.72 PKM (1.00) PKMNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL17473547 0.72 DRD2 (0.40) PKMDRD2DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2980089-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-12-20 EP disclosed
EP-2980089-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-12-20 EP disclosed
US-20170174682-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-22 US disclosed
US-20170174682-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-22 US disclosed
US-20170174682-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-22 US disclosed
US-9637483-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-02 US disclosed
US-9637483-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-02 US disclosed
US-9637483-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-02 US disclosed
US-20160039811-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-11 US disclosed
US-20160039811-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-11 US disclosed
EP-1503998-B1 HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE MERCK SHARP & DOHME (GB) 2009-07-01 EP disclosed
US-20080070895-A1 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase COLLINS IAN J 2008-03-20 US disclosed
US-20080070895-A1 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase COLLINS IAN J 2008-03-20 US disclosed
US-20080070895-A1 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase COLLINS IAN J 2008-03-20 US disclosed
US-7282513-B2 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase MERCK SHARP & DOHME LIMITED (GB) 2007-10-16 US disclosed
US-7282513-B2 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase MERCK SHARP & DOHME LIMITED (GB) 2007-10-16 US disclosed
US-7282513-B2 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase MERCK SHARP & DOHME LIMITED (GB) 2007-10-16 US disclosed
US-20060173054-A1 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase MERCK SHARP & DOHME (UK) LIMITED (GB) 2006-08-03 US disclosed
US-7041689-B2 Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase MERCK SHARP & DOHME LTD. (GB) 2006-05-09 US disclosed
US-20050182109-A1 Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase MERCK SHARP & DOHME (UK) LIMITED (GB) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174682-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 PKM 967/4885NPC1 4602/4885RAB9A 1586/4885
US-20050182109-A1 Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase BACE1, BACE2, PSEN1 PKM 4612/4885NPC1 2080/4885RAB9A 2206/4885
US-20160039811-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 PKM 967/4885NPC1 4602/4885RAB9A 1586/4885
US-20060173054-A1 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase BACE1, BACE2, PSEN1 PKM 4534/4885NPC1 1347/4885RAB9A 1977/4885
US-20080070895-A1 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase BACE1, BACE2, PSEN1 PKM 4534/4885NPC1 1347/4885RAB9A 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.